Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
about
FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cellsAre we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphomaNext-generation prognostic assessment for diffuse large B-cell lymphomaTargeting the B-cell receptor signaling pathway in B lymphoid malignanciesConstitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell LymphomaTargeted therapies in CLL: mechanisms of resistance and strategies for managementBeyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphomaTargeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewSecond-generation inhibitors of Bruton tyrosine kinaseEvolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent updateA polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathwayThe myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteinsLenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cellsMature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Lenalidomide for the treatment of B-cell lymphoma.Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.A microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphomaSafety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.L-PROBe: A Novel Non-anthracycline Combination Chemotherapy Regimen for Aggressive B Cell Non-Hodgkin Lymphoma in Elderly Patients.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target eraToll-Like Receptors and Cancer: MYD88 Mutation and Inflammation.Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.Mutational analysis of primary central nervous system lymphoma.Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantationPoor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategiesLenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.Protein ubiquitination in lymphoid malignancies.Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.Lenalidomide induces degradation of IKZF1 and IKZF3.Identification of candidate B-lymphoma genes by cross-species gene expression profiling.Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.B-cell receptor signaling in diffuse large B-cell lymphoma.
P2860
Q24304887-7D52FDF9-C591-47A2-BB9C-E9A6058F2313Q24597424-77B7054A-3DE4-4934-8B41-D734CF95252BQ26738937-7CDBA83A-EF27-4A23-8641-ADFE363FCA96Q26796428-D5BF6501-3A2E-4526-B695-099C32D8A95CQ26828782-3BC16306-8F26-403F-8545-1A5B5B3C932BQ26853170-C1CADD88-73A4-456A-932C-3495C56ADC99Q27002528-B994F6CC-09BB-4151-856A-2168B7A76F05Q27013785-330B016C-42D7-46FD-9285-7C8EA2CC09A9Q27025812-CF57942D-FB33-415C-A671-36A96D246010Q27304386-36CAA887-7B66-4D33-AA6E-950C7B6D5E63Q28076118-B4316009-C279-4EBE-9710-55F0B30D22ECQ28078869-C8848C50-94D4-4ECC-AB16-D1C1FB0F5B2FQ28302540-2009672E-322E-4F13-ABF2-4FEADAF97C53Q28303081-47DE05C6-316A-4B05-9141-0B306E89FE69Q28303091-863651D6-3EB6-41E3-977D-FE89E3F7A3DEQ30240133-A888B5A8-B307-4BBF-AADA-CD1CCB8AA569Q30249007-A3F7E7B4-2E94-4E03-9FF1-28E6BC2C33E3Q30303054-776FEBEF-C330-4294-9576-7ACC4CD55400Q30375911-B1D92388-37E4-4A5F-9785-3B6C684C6463Q30433183-22839362-665D-42F0-BBC7-28E09E69B33BQ30485971-9800A264-DE17-4B5F-8032-7E127AD44A94Q33418964-524FF91A-2139-4DEE-858D-93C95C7424C8Q33439291-0B549405-D045-4908-BE4B-5DC1FE0624B1Q33622342-E7450025-951C-44A9-A196-D32538D25ABCQ33909086-C3A47E6E-64B8-481D-B9C3-B2A8015FA127Q33978723-66B3755F-688C-4735-B808-21F3A0397C01Q34039406-BA0DA4BA-A26E-4D45-B6FC-129AB203621BQ34104139-70F80059-5876-4E2D-AA85-A557677E7621Q34137016-567393B4-35A7-45E6-9ACE-FB4F834CCC58Q34325329-11C43193-8C31-4A6D-B6A8-AF9F90519994Q34390837-CB2D0F81-2FD7-41EB-B1A0-E85BD1F52E4DQ34483086-1D3B3F6D-CD34-477B-B63B-020647091561Q34722000-CE35A3A7-A1B5-48AC-B655-233EC5DB2B29Q34722684-B63183C4-823D-4882-83E9-7BA528C9914BQ34860750-E2786303-DEED-461C-B382-B17183C6A97CQ34882773-135771AE-D8B0-45EB-88D3-E2638DA14FC6Q34934048-B5FB3794-81FE-4F5D-97B4-B203EF2DEB5CQ35018604-FBD0651A-D117-47D2-AE85-0B94450FFFF5Q35171777-BCC5C28D-6EF2-4CA5-8425-97356C1E3997Q35218042-7140A1C4-9E3B-49CA-9EBB-1EEB784FAC50
P2860
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
@nl
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
@ast
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
@en
type
label
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
@nl
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
@ast
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
@en
prefLabel
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
@nl
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
@ast
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
@en
P2093
P2860
P3181
P1433
P1476
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
@en
P2093
Arthur L Shaffer
Craig Thomas
George Wright
Holger Kohlhammer
John Powell
Joseph J Buggy
Lesley A Mathews
Louis M Staudt
Marc Ferrer
P2860
P304
P3181
P356
10.1016/J.CCR.2012.05.024
P577
2012-06-01T00:00:00Z